Biomarker Expertise Firalis specializes in biomarker discovery, validation and integration for diagnostic, prognostic and theranostic applications, presenting a strong opportunity to pair with pharma and diagnostics companies seeking targeted biomarker panels and companion diagnostics.

R&D Services End-to-end biomarker related CRO services including proteomics, genomics, flow cytometry, assay development, biobanking and regulatory support position Firalis as a go-to partner for customers aiming to accelerate biomarker qualification and regulatory submissions.

I V D Capabilities A portfolio spanning RUO kits and IVD tools enables Firalis to engage early research customers and upgrade to validated diagnostic solutions, creating upsell opportunities with pharma, biotech and clinical labs seeking validated biomarker platforms.

Strategic Funding Recent France 2030 funding and strategic acquisitions (e.g., sequencing capacities) indicate growing scale and investment potential, signaling opportunities to partner on large projects, joint development initiatives and capability expansions.

Clinical & Safety Focus Emphasis on drug safety, efficacy, patient stratification and personalized medicine aligns Firalis with pharmaceutical clients pursuing precision medicine programs, offering collaboration on translational studies, biomarker qualification and companion diagnostic development.